Quarterly report · Q1
2385.TEDINET S100S775
Period2023-07-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.1bn | 2023-07-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥8.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.2bn | 2022-07-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | −¥501m | 2023-07-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥46m | 2022-07-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | −¥496m | 2023-07-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥46m | 2022-07-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥497m | 2023-07-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥46m | 2022-07-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥527m | 2023-07-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥452m | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥528m | 2023-07-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥16m | 2022-07-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥7.4bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥7.9bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥902m | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.1bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2023-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥-20.15 | 2023-07-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.27 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.53 | 2022-07-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 85.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue external | 2023-07-01 → 2023-09-30 | ¥600,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-09-30 | −¥78m |
| jpcrp040300-q1r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥57m |
| jpcrp040300-q1r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥57m |
| jpcrp040300-q1r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥11m |
| jpcrp040300-q1r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥166m |
| jpcrp040300-q1r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥166m |
| jpcrp040300-q1r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥148m |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥677m |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥676m |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥645,000 |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥267m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥71m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥67m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | segment profit | 2023-07-01 → 2023-09-30 | −¥8m |
| jpcrp040300-q1r_E05367-000Health Care Support Servicereportable segment | revenue | 2023-07-01 → 2023-09-30 | ¥157m |
| jpcrp040300-q1r_E05367-000Health Care Support Servicereportable segment | revenue external | 2023-07-01 → 2023-09-30 | ¥157m |
| jpcrp040300-q1r_E05367-000Health Care Support Servicereportable segment | segment profit | 2023-07-01 → 2023-09-30 | ¥11m |
| —segment total | revenue | 2023-07-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue external | 2023-07-01 → 2023-09-30 | ¥1.1bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-09-30 | ¥4m |
| —segment total | segment profit | 2023-07-01 → 2023-09-30 | −¥423m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | ¥600,000 |
| Reconciling Itemsreconciling | revenue external | 2022-07-01 → 2022-09-30 | ¥600,000 |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥77m |
| jpcrp040300-q1r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥89m |
| jpcrp040300-q1r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥89m |
| jpcrp040300-q1r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2022-07-01 → 2022-09-30 | −¥13m |
| jpcrp040300-q1r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q1r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q1r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥282m |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥732m |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥732m |
| jpcrp040300-q1r_E05367-000Functional Food Retailingreportable segment | segment profit | 2022-07-01 → 2022-09-30 | −¥184m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥138m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥138m |
| jpcrp040300-q1r_E05367-000Functional Material Developmentreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥23m |
| jpcrp040300-q1r_E05367-000Health Care Support Servicereportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥148m |
| jpcrp040300-q1r_E05367-000Health Care Support Servicereportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥148m |
| jpcrp040300-q1r_E05367-000Health Care Support Servicereportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥15m |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥2.2bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥2.2bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥123m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 310
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |